Literature DB >> 12636256

Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy.

Shiro Ibe1, Naomi Shibata, Makoto Utsumi, Tsuguhiro Kaneda.   

Abstract

We detected several types of human immunodeficiency virus type 1 (HIV-1) variants with an insertion mutation in the p6(gag)and p6(pol) genes in eight of twenty-two (36.4%) patients who possessed drug-resistant viruses under highly active antiretroviral therapy (HAART). It was characteristic that a conserved proline-rich motif "PTAPP" in the N-terminus of p6(gag) protein was completely or partially duplicated in all cases. Five among the eight cases were retrospectively investigated in terms of the occurrence of dynamic change in the gag gene between the inserted and wild-type HIV-1 in the course of HAART. The longitudinal analysis revealed the following: 1) The inserted-type viruses were selected over the wild-type during HAART in three cases in which the both types coexisted in the beginning of the therapy. 2) In two cases in which the inserted-type HIV-1 alone was detected before the beginning of HAART, the inserted-type HIV-1 alone was continuously detected during the therapy. The inserted-type HIV-1 was also detected in four of thirty-nine (10.3%) therapy-naive patients. However, the frequency of inserted-type HIV-1 detection in the HAART-receiving patients is significantly higher than that in the therapy-naive patients (P = 0.02). These results suggest that this type of insertion mutation is a polymorphism of the p6(gag) and p6(pol) genes, however, it consequently gave an advantage on proliferation and/or survival of the HIV-1 variant under the presence of antiretroviral drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636256     DOI: 10.1111/j.1348-0421.2003.tb02788.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  16 in total

Review 1.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

2.  Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.

Authors:  Andreas Leiherer; Christine Ludwig; Ralf Wagner
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

3.  C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.

Authors:  Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Authors:  Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

5.  The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.

Authors:  Susan M Watanabe; Viviana Simon; Natasha D Durham; Brittney R Kemp; Satoshi Machihara; Kimdar Sherefa Kemal; Binshan Shi; Brian Foley; Hongru Li; Benjamin K Chen; Barbara Weiser; Harold Burger; Kathryn Anastos; Chaoping Chen; Carol A Carter
Journal:  Retrovirology       Date:  2016-09-06       Impact factor: 4.602

6.  Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.

Authors:  Sadahiro Tamiya; Sek Mardy; Mark F Kavlick; Kazuhisa Yoshimura; Hiroaki Mistuya
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance.

Authors:  Jianhong Cao; John McNevin; Matthew McSweyn; Yi Liu; James I Mullins; M Juliana McElrath
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

8.  Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.

Authors:  Ujjwal Neogi; Shwetha D Rao; Irene Bontell; Jens Verheyen; Vasudev R Rao; Sagar C Gore; Neelesh Soni; Anita Shet; Eugen Schülter; Maria L Ekstrand; Amogne Wondwossen; Rolf Kaiser; Mallur S Madhusudhan; Vinayaka R Prasad; Anders Sonnerborg
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

9.  PTAP motif duplication in the p6 Gag protein confers a replication advantage on HIV-1 subtype C.

Authors:  Shilpee Sharma; Prabhu S Arunachalam; Malini Menon; Viswanath Ragupathy; Ravi Vijaya Satya; Joshua Jebaraj; Shambhu Ganeshappa Aralaguppe; Chaitra Rao; Sreshtha Pal; Shanmugam Saravanan; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Suniti Solomon; Indira Hewlett; Udaykumar Ranga
Journal:  J Biol Chem       Date:  2018-05-17       Impact factor: 5.157

Review 10.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.